20-F: InflaRx Shifts Focus to Izicopan, Cuts GOHIBIC Commercial Efforts

InflaRx N.V. reported a net loss of €45.6 million for 2025, shifting its strategic focus to the oral C5aR inhibitor izicopan after discontinuing active commercialization of GOHIBIC (vilobelimab) in the U.S. due to lack of commercial success.

Summary

• InflaRx N.V. reported a net loss of €45.6 million for the fiscal year ended December 31, 2025, compared to €46.1 million in 2024.
• Accumulated deficit reached €377.8 million as of December 31, 2025.
• Revenues from GOHIBIC (vilobelimab) product sales decreased significantly to €29,331 in 2025 from €165,789 in 2024.
• Cost of sales increased by €4.0 million to €7.3 million in 2025, primarily due to a full write-down of GOHIBIC inventory following the discontinuation of active U.S. commercialization.
• Marketing and sales expenses decreased by €2.3 million to €4.5 million in 2025 due to significant reductions in commercial spending and workforce for GOHIBIC.
• Research and development expenses decreased by €9.6 million to €25.7 million in 2025, mainly from lower third-party costs in manufacturing development and clinical trials.
• The company is prioritizing the development of its oral C5aR inhibitor, izicopan, for chronic autoimmune and inflammatory conditions, with positive Phase 2a data reported in Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU).
• GOHIBIC (vilobelimab) received Emergency Use Authorization (EUA) from the FDA in April 2023 for critically ill, invasively mechanically ventilated COVID-119 patients, and European marketing authorization under exceptional circumstances in January 2025.
• InflaRx will continue to review partnering opportunities for GOHIBIC in the U.S. and Europe and maintain reactive supply in the U.S. under its EUA.
• The company completed an underwritten public offering in February 2025, raising €26.8 million ($28.0 million) in net proceeds from ordinary shares and pre-funded warrants.
• Cash and cash equivalents were €16.0 million and marketable securities were €30.2 million as of December 31, 2025.
• The company believes its existing financial resources will fund operations for at least the next 12 months into mid-2027, but substantial additional funding will be required for further izicopan clinical development.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for InflaRx, marked by significant commercial failure of GOHIBIC and ongoing substantial losses, despite promising early-stage data for izicopan and successful capital raises. The strategic pivot is necessary but highlights past missteps and future funding dependency.

Positives

• Net loss slightly decreased to €45.6 million in 2025 from €46.1 million in 2024.
• Research and development expenses decreased by €9.6 million in 2025, reflecting cost optimization.
• Izicopan showed positive Phase 2a clinical study results in Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU), with efficacy measures differentiated from placebo and in line with approved therapies.
• Initial data from HS patients in the 4-week off-drug follow-up period showed continued deepening of HiSCR responses, suggesting durable clinical benefit.
• Izicopan demonstrated a favorable safety profile in Phase 1 and Phase 2a studies, with no serious adverse events reported.
• GOHIBIC (vilobelimab) received marketing authorization under exceptional circumstances by the European Commission in January 2025 for SARS-CoV-2-induced ARDS.
• GOHIBIC (vilobelimab) was selected for a BARDA-sponsored clinical trial to evaluate novel host-directed therapeutics for broader ARDS.
• The company successfully raised €26.8 million ($28.0 million) in net proceeds from a public offering in February 2025, strengthening its capital position.
• The company has a robust clawback policy in place to ensure accountability and alignment of executive compensation with long-term financial performance.

Negatives

• Revenues from GOHIBIC (vilobelimab) product sales significantly decreased by €136,458 to €29,331 in 2025, indicating poor commercial success.
• Cost of sales increased by €4.0 million, primarily due to a full write-down of GOHIBIC inventory totaling €7.3 million, reflecting the discontinuation of active U.S. commercialization.
• The Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) was stopped in May 2025 due to futility based on an interim analysis of the first 30 patients.
• The company has a history of significant operating losses and expects to incur comparable or increasing net operating losses for the foreseeable future.
• An accumulated deficit of €377.8 million as of December 31, 2025, highlights ongoing financial challenges.
• The company's existing cash and cash equivalents are not sufficient to fund the completion of development for any of its product candidates, requiring substantial additional funding.
• The company's public float has fluctuated around the $75 million threshold, and if it falls below this, it may be subject to the Baby Shelf Limitation, restricting capital raising ability.
• The company's ability to use net operating loss carryforwards may be limited by German and U.S. tax rules, potentially increasing future tax liability.
• The company believes it was likely a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes in 2022, 2023, 2024, and 2025, which could result in adverse U.S. federal income tax consequences for U.S. investors.

Risks

• Risk of never achieving or maintaining profitability and of investors losing their entire investment due to significant operating losses and limited product revenue.
• Risk related to not obtaining additional funding or securing strategic potential partnerships, which could force delays, reductions, or elimination of product discovery, development programs, or commercialization efforts.
• Risks related to limited operating history and history of commercializing pharmaceutical products, making it difficult to evaluate future viability.
• Risk related to regulatory oversight over GOHIBIC (vilobelimab) EUA and market authorization, which may lead to withdrawal or revocation if underlying requirements or conditions are no longer met.
• Risk of possible occurrence of clinical failure at any stage of clinical development, as success in early trials does not guarantee later success, and novel C5a/C5aR inhibition is partly unproven.
• Risk of incurring additional significant expenses in connection with ongoing regulatory obligations and continued regulatory review of GOHIBIC and any other approved product candidates.
• Risk if product candidates cause or are perceived to cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial profile, or result in negative consequences post-approval.
• Risk of reliance on third parties to conduct clinical trials, which limits control and could lead to delays or adverse impacts if they do not perform satisfactorily.
• Risk of dependence on foreign third-party manufacturers and suppliers, increasing the risk of obtaining adequate, timely, and cost-effective product candidates and products due to political/economic disruptions, tariffs, or supply chain issues.
• Risk that the process of manufacturing biologics, such as vilobelimab, is extremely susceptible to product loss due to contamination, equipment failure, or other disruptions.
• Risk that manufacturing processes are subject to quality control risks and related regulatory requirements, potentially leading to sanctions or supply interruptions.
• Risks related to obtaining, maintaining, protecting, defending, and enforcing patent, trade secret, and other intellectual property protection, which may be challenged, narrowed, or invalidated by third parties.
• Risk of having a limited number of employees to manage and operate the business, potentially hindering development and operations.
• Risk of disruption to the business as a result of managing growth in business operations and number of personnel.
• Risk of liability to the business by improper activities of employees and third-party contractors, including non-compliance with regulatory standards.
• Risks related to the trading price of ordinary shares being highly volatile, potentially resulting in substantial losses and inviting securities litigation.
• Risk associated with being a foreign private issuer and not being subject to U.S. proxy rules or following Nasdaq listing requirements, potentially offering fewer shareholder protections.
• Risk of business impact resulting from financial markets, changes to political and regulatory policies, and general economic conditions, including inflation, supply chain disruptions, and geopolitical instability.
• Risk of legal, regulatory, or market measures to address environmental objectives negatively affecting the business or operations.
• Risk of dilution to shareholders through raising capital, or restriction/relinquishment of rights to technologies and product candidates if additional funding is obtained through collaborations.
• Risk of facing substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies.
• Risk of product liability lawsuits, which could result in substantial liabilities and limit commercialization.
• Risk of cyber incidents or other failures in IT systems resulting in information theft, data corruption, and significant disruption of business operations.
• Risk that the legal and regulatory environment related to data privacy is becoming stricter, leading to additional costs or changes in personal information handling, and potential fines or litigation for non-compliance.
• Risk of internal controls over financial reporting failing to be effective, leading to material misstatements and loss of investor confidence.
• Banking system risk, where cash balances at third-party financial institutions in excess of insurance limits could be threatened by bank insolvency.

Future Outlook

InflaRx plans to prioritize izicopan as its leading pipeline asset, aiming for Phase 2b readiness in Hidradenitis Suppurativa (HS) and evaluating further development options in Chronic Spontaneous Urticaria (CSU) and ANCA-associated vasculitis (AAV). The company intends to conduct a PK bridging study in China in 2026 to enable expedited proof-of-concept studies for izicopan in additional inflammation and immunology (I&I) indications. Discussions with potential collaborators for izicopan and vilobelimab in selected indications/territories are ongoing. For vilobelimab, the company will explore expanding its label into other critical care indications, potentially through the BARDA study in broader ARDS or with commercial partners for virally induced ARDS. Active commercialization of GOHIBIC (vilobelimab) in the U.S. has ceased, with the company seeking commercial partnerships for GOHIBIC in the U.S. and Europe. Pre-clinical development for IFX002, a fully humanized anti-C5a antibody with a longer half-life, will continue as a life-cycle management product for vilobelimab.

Management Comments

• We are prioritizing efforts and resources towards the development of our orally available C5aR inhibitor izicopan.
• We believe izicopan is a promising product candidate for being developed in several disease areas of inflammation, where orally available therapeutics are not available or do not meet the medical need.
• We anticipate meeting with the FDA to determine a potential development path forward in PG (pyoderma gangrenosum) for vilobelimab.
• We intend to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies for additional indications in China and additional geographies for izicopan.
• We continue our concurrent strategy to foster discussions with potential collaborators for izicopan.
• We will keep GOHIBIC (vilobelimab) available for ordering inside the U.S. under its emergency use authorization and maintain the ability to satisfy GOHIBIC (vilobelimab) demand in the U.S. on a reactive basis.
• In Europe, GOHIBIC has not been launched and we will only consider launching it in conjunction with a potential commercial partner.
• We believe our existing cash and cash equivalents and financial assets will enable us to fund our operating expenses and capital expenditure requirements under our current business plan for at least the next 12 months into mid-2027.

Industry Context

StockSavvy.ai notes that InflaRx's strategic shift to prioritize izicopan, an oral small molecule C5aR inhibitor, aligns with a broader industry trend towards more convenient, orally administered therapies for chronic inflammatory and autoimmune diseases. The discontinuation of active commercialization for GOHIBIC in severe COVID-19 reflects the evolving landscape of the pandemic and the challenges of commercializing niche products, especially those with EUA status. The focus on complement system inhibition remains a high-potential area in biopharma, with companies like Amgen (targeting C5aR with avacopan) and others exploring similar pathways. The pursuit of partnerships for both izicopan and GOHIBIC indicates a pragmatic approach to leverage external resources and expertise in a capital-intensive industry, particularly given the company's ongoing losses and need for additional funding.

Comparison to Industry Standards

• Izicopan has shown potential for superior characteristics to the only approved C5aR inhibitor, avacopan (marketed by Amgen for ANCA-associated vasculitis), in preclinical and clinical pharmacology studies, demonstrating higher plasma exposure and improved inhibitory activity.
• In HS, izicopan's 4-week efficacy data are largely in line with data reported for the same timepoint from clinical studies for approved HS therapies (e.g., adalimumab, secukinumab, bimekizumab) and compared favorably for reductions in draining tunnels (dT) and improvement in NRS30 pain response.
• In CSU, izicopan's reported improvements in UAS7 appeared generally higher in the 60 mg dosing cohort (UAS7 change from baseline of -13.7 points at Week 4) and indicate a level of activity that exceeds average historically reported placebo levels and is within the range of existing approved CSU therapies (e.g., omalizumab, dupilumab, remibrutinib).
• Vilobelimab is the first C5a monoclonal antibody to enter clinical development and the only approved therapy specifically targeting C5a, differentiating it from C5 inhibitors like eculizumab (Alexion Pharmaceuticals) which block MAC formation and may not fully control C5a signaling.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in legal proceedings that arise in the ordinary course of business, but believes the outcome of these, if determined adversely, will not have a material adverse effect on its financial position.
• No material adverse litigation or damages paid in connection with litigation during the period covered by the financial statements.

Related Party Transactions

• Entered into indemnification agreements with directors and senior management, requiring the company to indemnify them to the fullest extent permitted by law, with exceptions for malice, gross negligence, intentional recklessness, and serious culpability.
• Compensation of executive management and non-executive directors includes short-term employee benefits and share-based payments, with certain amounts accrued but not yet paid as of December 31, 2025.

Stakeholder Impact

• Shareholders: Face dilution risk from future equity offerings and potential adverse U.S. federal income tax consequences if the company remains a PFIC. The stock price is highly volatile, and the company does not anticipate paying cash dividends.
• Employees: Experienced a significant workforce reduction in December 2025/January 2026 due to the restructuring and discontinuation of GOHIBIC commercial activities, particularly impacting those in commercialization and late-stage development roles.
• Customers (Hospitals): GOHIBIC (vilobelimab) will remain available for ordering in the U.S. under its EUA on a reactive basis, but active commercialization efforts have ceased, potentially affecting direct engagement and support.
• Patients: Continued development of izicopan aims to address unmet medical needs in chronic inflammatory conditions like HS and CSU. The discontinuation of active GOHIBIC commercialization might impact access or awareness for COVID-19 patients, though supply is maintained.
• Creditors: The company's ongoing operating losses and reliance on future capital raises present a material uncertainty regarding its ability to continue as a going concern, which could impact creditors.

Next Steps

• Proceed with clinical development of izicopan toward Phase 2b readiness in Hidradenitis Suppurativa (HS).
• Continue to evaluate development options for izicopan in Chronic Spontaneous Urticaria (CSU), ANCA-associated vasculitis (AAV), and potentially other inflammation and immunology (I&I) indications.
• Conduct a PK bridging study in China in 2026 for izicopan to enable expedited proof of concept studies in China and additional geographies.
• Foster discussions with potential collaborators for joint development of izicopan and vilobelimab in selected indications and/or territories.
• Explore the possibility of expanding the label for vilobelimab in the area of ARDS, including through the BARDA study or with commercial partners for virally induced ARDS.
• Seek commercial partners for GOHIBIC (vilobelimab) in the U.S. and Europe, while maintaining reactive supply in the U.S. under its EUA.
• Pursue further pre-clinical development of IFX002 to prepare for potential clinical development as a life-cycle management product for vilobelimab.
• Meet with the FDA to determine a potential development path forward for vilobelimab in pyoderma gangrenosum (PG).
• Regain compliance with Nasdaq's Minimum Bid Price Rule by September 7, 2026, or apply for transfer to The Nasdaq Capital Market.

Key Dates

Recommendation

InflaRx is undergoing a significant strategic pivot, shifting resources from the commercially unsuccessful GOHIBIC to the promising izicopan. While the positive Phase 2a data for izicopan in HS and CSU are encouraging and the company has successfully raised capital, the commercial failure of GOHIBIC and the futility stop of the PG trial for vilobelimab represent substantial setbacks. The company faces ongoing significant losses and a material uncertainty about its going concern status, necessitating further substantial funding. The stock is highly volatile, and while the new focus on izicopan offers potential upside, the execution risk for Phase 2b and securing partnerships is high. A 'hold' recommendation is appropriate as investors should await clearer signs of izicopan's continued clinical success and the securing of necessary funding and partnerships before considering a stronger position.

Keywords

Biopharmaceutical, Complement System, C5a Inhibitor, C5aR Inhibitor, Izicopan, Vilobelimab, GOHIBIC, Hidradenitis Suppurativa, Chronic Spontaneous Urticaria, ARDS, COVID-19, Clinical Trials, Drug Development, Biotechnology, SEC Filing, Financial Results, R&D, Orphan Drug, EUA, Marketing Authorization